Media headlines about Female Health Company (The) (NASDAQ:VERU) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Female Health Company (The) earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4034362545324 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Female Health Company (The) (NASDAQ:VERU) last issued its earnings results on Tuesday, August 8th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.05. The company had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $2.20 million. Female Health Company (The) had a negative return on equity of 16.78% and a negative net margin of 42.02%.

VERU has been the subject of a number of analyst reports. HC Wainwright set a $5.00 price objective on Female Health Company (The) and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Rodman & Renshaw initiated coverage on Female Health Company (The) in a research report on Wednesday, July 26th. They set a “buy” rating and a $5.00 price objective for the company. Finally, ValuEngine downgraded Female Health Company (The) from a “hold” rating to a “sell” rating in a research report on Friday, July 28th.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/25/female-health-company-the-veru-earns-media-impact-rating-of-0-10.html.

In related news, Director Harry Fisch bought 34,250 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $51,717.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mitchell Shuster Steiner bought 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were bought at an average price of $1.63 per share, with a total value of $163,000.00. Following the completion of the acquisition, the insider now directly owns 7,764,767 shares in the company, valued at $12,656,570.21. The disclosure for this purchase can be found here. Insiders have purchased a total of 146,975 shares of company stock valued at $234,279 over the last 90 days. 10.90% of the stock is currently owned by company insiders.

About Female Health Company (The)

Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Receive News & Stock Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related stocks with our FREE daily email newsletter.